Seven-year clinical outcomes after collagenase injection in patients with Dupuytren's disease: A prospective study: Journal of Orthopaedics

R. De Vitis; M. Passiatore; A. Perna; S. Careri; V. Cilli; G. Taccardo

doi:10.1016/j.jor.2020.03.028

Seven-year clinical outcomes after collagenase injection in patients with Dupuytren's disease: A prospective study: Journal of Orthopaedics

R. De Vitis, M. Passiatore, A. Perna, S. Careri, V. Cilli, G. Taccardo

Research output: Contribution to journal › Article › peer-review

Abstract

Introduction: This investigation is a prospective cohort study examining the use of Clostridium histolyticum collagenase injection (CCH) for the treatment of Dupuytren's disease (DD) with a 7 years follow-up. Methods: Forty-five monodigital DD patients were injected with CCH on a single joint. Assessment included measurement of residual passive extension deficit (PED), function (using QuickDASH) and patient satisfaction. Results: 86.7% of PIPJ and 65.6% of MPJ had a worsening of PED. Nevertheless, thirty-nine patients (86.7%) concluded their treatment with only one injection, without any further treatment. Conclusion: CCH provides a long-term effective solution. Recurrence occurs, especially in PIPJ, with acceptable rates. © 2020 Professor P K Surendran Memorial Education Foundation

Original language	English
Pages (from-to)	218-222
Number of pages	5
Journal	J. Orthop.
Volume	21
DOIs	https://doi.org/10.1016/j.jor.2020.03.028
Publication status	Published - 2020

Keywords

Collagenase injection
Dupuytren
Hand function
Recurrence rate
Seven years
collagenase
aged
Article
clinical article
clinical outcome
Clostridium histolyticum
cohort analysis
controlled study
Disabilities of the Arm, Shoulder and Hand (score)
drug efficacy
drug safety
Dupuytren contracture
ecchymosis
edema
female
follow up
human
lymphadenitis
male
metacarpophalangeal joint
multicenter study
observational study
patient satisfaction
priority journal
prospective study
proximal interphalangeal joint
QuickDASH
recurrence risk
skin defect
swelling

Access to Document

10.1016/j.jor.2020.03.028

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85082755820&doi=10.1016%2fj.jor.2020.03.028&partnerID=40&md5=c43d65e69137e940c1e509ec703117c8

Cite this

@article{99c33aebd2da48a0b23aa3b040b01487,

title = "Seven-year clinical outcomes after collagenase injection in patients with Dupuytren's disease: A prospective study: Journal of Orthopaedics",

abstract = "Introduction: This investigation is a prospective cohort study examining the use of Clostridium histolyticum collagenase injection (CCH) for the treatment of Dupuytren's disease (DD) with a 7 years follow-up. Methods: Forty-five monodigital DD patients were injected with CCH on a single joint. Assessment included measurement of residual passive extension deficit (PED), function (using QuickDASH) and patient satisfaction. Results: 86.7% of PIPJ and 65.6% of MPJ had a worsening of PED. Nevertheless, thirty-nine patients (86.7%) concluded their treatment with only one injection, without any further treatment. Conclusion: CCH provides a long-term effective solution. Recurrence occurs, especially in PIPJ, with acceptable rates. {\textcopyright} 2020 Professor P K Surendran Memorial Education Foundation",

keywords = "Collagenase injection, Dupuytren, Hand function, Recurrence rate, Seven years, collagenase, aged, Article, clinical article, clinical outcome, Clostridium histolyticum, cohort analysis, controlled study, Disabilities of the Arm, Shoulder and Hand (score), drug efficacy, drug safety, Dupuytren contracture, ecchymosis, edema, female, follow up, human, lymphadenitis, male, metacarpophalangeal joint, multicenter study, observational study, patient satisfaction, priority journal, prospective study, proximal interphalangeal joint, QuickDASH, recurrence risk, skin defect, swelling",

author = "{De Vitis}, R. and M. Passiatore and A. Perna and S. Careri and V. Cilli and G. Taccardo",

note = "Cited By :6 Export Date: 19 March 2021 Correspondence Address: Passiatore, M.; Istituto di Clinica Ortopedica. Fondazione Policlinico Universitario A. Gemelli IRCCS, Via Giuseppe Moscati 31, Italy; email: passiatore.m@gmail.com",

year = "2020",

doi = "10.1016/j.jor.2020.03.028",

language = "English",

volume = "21",

pages = "218--222",

journal = "J. Orthop.",

issn = "0972-978X",

publisher = "Reed Elsevier India Pvt. Ltd.",

}

TY - JOUR

T1 - Seven-year clinical outcomes after collagenase injection in patients with Dupuytren's disease: A prospective study

T2 - Journal of Orthopaedics

AU - De Vitis, R.

AU - Passiatore, M.

AU - Perna, A.

AU - Careri, S.

AU - Cilli, V.

AU - Taccardo, G.

N1 - Cited By :6 Export Date: 19 March 2021 Correspondence Address: Passiatore, M.; Istituto di Clinica Ortopedica. Fondazione Policlinico Universitario A. Gemelli IRCCS, Via Giuseppe Moscati 31, Italy; email: passiatore.m@gmail.com

PY - 2020

Y1 - 2020

N2 - Introduction: This investigation is a prospective cohort study examining the use of Clostridium histolyticum collagenase injection (CCH) for the treatment of Dupuytren's disease (DD) with a 7 years follow-up. Methods: Forty-five monodigital DD patients were injected with CCH on a single joint. Assessment included measurement of residual passive extension deficit (PED), function (using QuickDASH) and patient satisfaction. Results: 86.7% of PIPJ and 65.6% of MPJ had a worsening of PED. Nevertheless, thirty-nine patients (86.7%) concluded their treatment with only one injection, without any further treatment. Conclusion: CCH provides a long-term effective solution. Recurrence occurs, especially in PIPJ, with acceptable rates. © 2020 Professor P K Surendran Memorial Education Foundation

AB - Introduction: This investigation is a prospective cohort study examining the use of Clostridium histolyticum collagenase injection (CCH) for the treatment of Dupuytren's disease (DD) with a 7 years follow-up. Methods: Forty-five monodigital DD patients were injected with CCH on a single joint. Assessment included measurement of residual passive extension deficit (PED), function (using QuickDASH) and patient satisfaction. Results: 86.7% of PIPJ and 65.6% of MPJ had a worsening of PED. Nevertheless, thirty-nine patients (86.7%) concluded their treatment with only one injection, without any further treatment. Conclusion: CCH provides a long-term effective solution. Recurrence occurs, especially in PIPJ, with acceptable rates. © 2020 Professor P K Surendran Memorial Education Foundation

KW - Collagenase injection

KW - Dupuytren

KW - Hand function

KW - Recurrence rate

KW - Seven years

KW - collagenase

KW - aged

KW - Article

KW - clinical article

KW - clinical outcome

KW - Clostridium histolyticum

KW - cohort analysis

KW - controlled study

KW - Disabilities of the Arm, Shoulder and Hand (score)

KW - drug efficacy

KW - drug safety

KW - Dupuytren contracture

KW - ecchymosis

KW - edema

KW - female

KW - follow up

KW - human

KW - lymphadenitis

KW - male

KW - metacarpophalangeal joint

KW - multicenter study

KW - observational study

KW - patient satisfaction

KW - priority journal

KW - prospective study

KW - proximal interphalangeal joint

KW - QuickDASH

KW - recurrence risk

KW - skin defect

KW - swelling

U2 - 10.1016/j.jor.2020.03.028

DO - 10.1016/j.jor.2020.03.028

M3 - Article

VL - 21

SP - 218

EP - 222

JO - J. Orthop.

JF - J. Orthop.

SN - 0972-978X

ER -

Seven-year clinical outcomes after collagenase injection in patients with Dupuytren's disease: A prospective study: Journal of Orthopaedics

Abstract

Keywords

Access to Document

Fingerprint

Cite this